Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen (COVIDOLIP)

June 19, 2020 updated by: Centre Hospitalier Universitaire Dijon
SARS-COV 2 infection might be responsible for sever pneumonia. Obesity seems to be a risk factor for severe SARS-COV 2 pneumonia. Lipid metabolism alteration are described with both obesity and sepsis. The aim of the present study was to describe association between lipid metabolism, obesity, sepsis inflammation and clinical outcome in COVID-19 patient with severe pneumonia compared with severe pneumonia caused by other pathogenes.

Study Overview

Study Type

Observational

Enrollment (Actual)

62

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Dijon, France, 21000
        • Chu Dijon Bourgogne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patient with pneumopathy

Description

Inclusion Criteria:

  • 2 of the following criteria: Cough/ Dyspnea/ Spitting/ Thoracic pain/ Hyperthermia (>=38 °C) Hypothermia (< 35°C) AND new radiologic pulmonary infiltrate
  • At admission or within 48 hours following hospital admission
  • With 2 qSOFA criteria: MAP =< 100 mmHg, Respiratory Rate >= 22, Glasgow score < 15 OR on mechanical ventilation OR under vasopressor
  • Age > 18
  • affiliated to social security

Exclusion Criteria:

  • Pregnancy
  • immunodepression
  • Pathology known to cause severe lymphopenia
  • hospitalisation within 3 month before inclusion AND sepsis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
COVID-19 severe pneumonia
bioassays carried out on samples already collected and conserved
Severe pneumonia due to other pathogene
bioassays carried out on samples already collected and conserved

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Cholesterol concentration
Time Frame: Within 48 hours following hospital admission
Within 48 hours following hospital admission

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
LDL cholesterol / HDL cholesterol/ Lipoprotein size and composition/ Non esterified Fatty acid/ Triglyceridemia/ CETP and PLTP activity/ apolipoprotein canceration/ lipid peroxidation/ Pro and anti inflammatory profile.
Time Frame: Within 48 hours following hospital admission
Ventilator free days (28 days)
Within 48 hours following hospital admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 7, 2020

Primary Completion (ACTUAL)

May 7, 2020

Study Completion (ACTUAL)

May 7, 2020

Study Registration Dates

First Submitted

June 16, 2020

First Submitted That Met QC Criteria

June 16, 2020

First Posted (ACTUAL)

June 17, 2020

Study Record Updates

Last Update Posted (ACTUAL)

June 23, 2020

Last Update Submitted That Met QC Criteria

June 19, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19 Severe Pneumonia

Clinical Trials on biological assays in particular on the lipid metabolism

3
Subscribe